key: cord-0771482-5g4kw3yq
authors: Wu, Qiuji; Zhang, Hongyan; Zhong, Yahua; Chua, Melvin L. K.; Xie, Conghua
title: Reply to Colorectal cancer and COVID‐19: Do we need to raise awareness and vigilance?
date: 2021-01-26
journal: Cancer
DOI: 10.1002/cncr.33218
sha: 9cf487967c1e1e8c7486ce8f65b79dd58da3fee9
doc_id: 771482
cord_uid: 5g4kw3yq

nan

We thank Niu et al for their interest in our article and their insightful comments regarding our results. 1 The authors pointed out a key finding of our study, namely that patients with gastrointestinal cancers constituted a high percentage of the patients with cancer who were infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and these individuals were more likely to develop severe coronavirus disease 2019 (COVID-19) when infected. It is interesting to note that Niu et al suggested a number of mechanisms that may underpin the vulnerability of patients with gastrointestinal cancer to COVID-19 infection. Specifically, the authors examined the expression of 2 key proteins, namely the angiotensin-converting enzyme 2 (ACE2) receptor and the transmembrane serine protease 2 (TMPRSS2), that mediate the entry of SARS-CoV-2 into human tissues. To this end, they analyzed gene expression data from the Gene Expression Profiling Interactive Analysis (GEPIA) database and found higher expression of both proteins in colorectal cancers compared with normal intestinal tissue. The authors thus rightfully raised their concerns regarding caring for patients with colorectal cancer during the ongoing COVID-19 pandemic. Here, we would like to investigate these points further relative to the published literature to date.

First, we agree with Niu et al that patients with gastrointestinal cancer constituted a substantial percentage of the patients with cancer in our cohort who were infected with SARS-CoV-2. 1 Our data regarding 107 patients with cancer who were diagnosed with COVID-19 demonstrated that approximately 18.7% of patients were diagnosed with gastrointestinal cancer. 1 This finding concurred with the other rates published by Wang et al (20.5%), 2 Lee et al (19%), 3 Yang et al (14%), 4 Dai et al (12.4%), 5 and Kuderer et al (12%) 6 demonstrating that gastrointestinal cancer was one of the most common malignancies among patients with cancer who contracted COVID-19. However, to truly ascertain the susceptibility of patients with a specific type of cancer to COVID-19, the correct test would be to first determine the prevalence of COVID-19 among all patients with gastrointestinal cancer and then compare that prevalence across different cancer types. Thus, we would examine the assumption that patients with gastrointestinal cancer are particularly susceptible to COVID-19.

We next examined the mechanisms proposed by the authors. Niu et al proposed a number of concepts based on their preliminary evidence regarding gene expression of key virus entry-associated proteins. SARS-CoV-2 attaches to the target cell surface through the engagement of the viral spike (S) protein and the extracellular ACE2 receptor. Separately, TMPRSS2 cleaves and primes the S protein and drives the fusion of viral and cellular membranes. 7 Similar to Niu et al, Bao et al 8 and Wang et al 2 also found that ACE2 and TMPRSS2 did demonstrate higher expression in patients with lung and gastrointestinal cancers compared with those with other malignancies. In addition, TMPRSS2 is regulated by testosterone and its metabolites, and therefore is suppressed by androgen deprivation therapy in patients with prostate cancer. It is interesting to note that early evidence has suggested that patients with prostate cancer who undergo androgen deprivation therapy may have a lower risk of SARS-CoV-2 infection. 9 Collectively, these direct and indirect correlative findings support the plausible notion that the gastrointestinal tract represents a path for infection with SARS-CoV-2. On this note, SARS-CoV-2 RNA and coronavirus virions have been detected in surgically resected rectal specimens. 10 Third, emerging data have indicated that a dysfunctional gut microbiota also might play a role in the pathogenesis of COVID-19. Certain compositions of the gut microbiota were suggested to be either positively or negatively associated with levels of inflammatory cytokines, and were predictive of severe COVID-19, possibly through the modulation of fecal metabolites and host Cancer March 15, 2021 immunity. 11 In patients with cancer, Bao et al found that expression of ACE2 and TMPRSS2 were associated with an abundance of specific bacterial genres, with Chlamydia being the top microbiota noted to be positively correlated with ACE2 expression in patients with colorectal cancer. 8 Nevertheless, to our knowledge, our understanding of the ways in which gut microbiota may influence the risk of COVID-19 in patients with cancer is limited. Therefore, this issue remains to be elucidated before strategies targeting microbial dysbiosis can be investigated.

Finally, regardless of whether patients with gastrointestinal cancer represent a subpopulation of individuals who are susceptible to COVID-19, the world currently is focused on the development of a vaccine to confer immunity to SARS-CoV-2 for patients with and without cancer. These vaccines are based on different rationales (eg, protein subunits, DNA-based or RNA-based vaccines, live attenuated or inactivated virus), and thus it is likely that efficacy may vary between them. Within this background, it is paramount that any mechanistic insights are informative regarding potential host factors that may blunt the effectiveness of these vaccines as opposed to simply establishing a link to infection. After all, nonpharmacological interventions already demonstrated the ability to affect large-scale containment of virus transmission.

No specific funding was disclosed.

Melvin L. K. Chua is supported by a National Medical Research Council Clinician-scientist award (NMRC/CSA/0027/2018) and has acted as a paid member of the advisory board and Speakers' Bureau for Janssen, has acted as a paid member of the advisory board for Astellas, has received honorarium and IT support for research from Varian, has received personal fees from MSD Oncology and Bayer, has received personal fees and nonfinancial support from AstraZeneca, has received personal fees from Illumina, and has received nonfinancial support from PV Med and Decipher Biosciences for work performed outside of the current study. Conghua Xie is supported by the Health Commission of Hubei Province Scientific Research Project (WJ2019H002); the Health Commission of Hubei Province Medical Leading Talent Project; Fundamental Research Funds for the Central Universities (2042018kf1037 and 2042019kf0329); the Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC2018005); and the Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (znpy2017049 and znpy2018070). The other authors made no disclosures.

Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan

Which type of cancer patients are more susceptible to the SARS-COX-2: evidence from a meta-analysis and bioinformatics analysis

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)

Direct evidence of active SARS-CoV-2 replication in the intestine

Gut microbiota may underlie the predisposition of healthy individuals to COVID-19